Management of infections in neutropenic patients: Advances in therapy and prevention

Judith Karp, W. G. Merz, J. D. Dick

Research output: Contribution to journalArticle

Abstract

The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.

Original languageEnglish (US)
Pages (from-to)405-411
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Volume6
Issue number3
StatePublished - 1993
Externally publishedYes

Fingerprint

Infection
Anti-Bacterial Agents
Hematopoietic System
Agranulocytosis
Induced Hyperthermia
Immunologic Factors
Routine Diagnostic Tests
Immune System
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Microbiology (medical)

Cite this

Management of infections in neutropenic patients : Advances in therapy and prevention. / Karp, Judith; Merz, W. G.; Dick, J. D.

In: Current Opinion in Infectious Diseases, Vol. 6, No. 3, 1993, p. 405-411.

Research output: Contribution to journalArticle

@article{9f8d325469cc4433a4d440275bc2ec80,
title = "Management of infections in neutropenic patients: Advances in therapy and prevention",
abstract = "The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.",
author = "Judith Karp and Merz, {W. G.} and Dick, {J. D.}",
year = "1993",
language = "English (US)",
volume = "6",
pages = "405--411",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Management of infections in neutropenic patients

T2 - Advances in therapy and prevention

AU - Karp, Judith

AU - Merz, W. G.

AU - Dick, J. D.

PY - 1993

Y1 - 1993

N2 - The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.

AB - The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027231177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027231177&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027231177

VL - 6

SP - 405

EP - 411

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 3

ER -